Meeting
2024 ASCO Genitourinary Cancers Symposium
Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy.
Authors
Neal D. Shore
Carolina Urologic Research Center, Genesis Care Clinics, Myrtle Beach, SC
Neal D. Shore , Bertrand F. Tombal , Maha H. A. Hussain , Fred Saad , Karim Fizazi , Cora N. Sternberg , E. David Crawford , Todd Fralich , Rui Li , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02799602
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 166)
DOI
10.1200/JCO.2024.42.4_suppl.166
Abstract #
166
Poster Bd #
G16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.
First Author: Patrick Heckman
Poster
2024 ASCO Annual Meeting
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.
First Author: Marc-Oliver Grimm
Poster
2024 ASCO Genitourinary Cancers Symposium
A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
First Author: Neal D. Shore
Poster
2023 ASCO Annual Meeting
Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).
First Author: Neal D. Shore